LICA PHARMACEUTICALS A/S Financials, key figures and credit report
Gross profit 359.4 kDKK FY 2025 +70.9% vs 2024
EBIT 359.4 kDKK FY 2025 +70.9% vs 2024
Net debt -2 528.3 kDKK FY 2025 -76.3% vs 2024
Quick ratio 11.4 FY 2025 +6.1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 370.72 | 312.60 | 234.22 | 210.30 | 359.45 |
| EBIT | 370.72 | 312.60 | 234.22 | 210.30 | 359.45 |
| Other financial income | 2 943.68 | 372.39 | 2 014.58 | 1 614.93 | 239.80 |
| Other financial expenses | -24.14 | -2 634.36 | -24.40 | -9.48 | -16.12 |
| Pre-tax profit | 3 290.26 | -1 949.37 | 2 224.41 | 1 815.75 | 583.12 |
| Income taxes | - 726.46 | 424.59 | - 493.34 | - 408.94 | - 132.41 |
| Net earnings | 2 563.81 | -1 524.79 | 1 731.07 | 1 406.82 | 450.71 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Non-current loans receivable | 20 230.29 | 17 727.72 | 21 123.47 | 22 118.10 | 21 512.70 |
| Long term receivables total | 20 230.29 | 17 727.72 | 21 123.47 | 22 118.10 | 21 512.70 |
| Inventories total | |||||
| Current trade debtors | 114.95 | 95.25 | 62.30 | 122.40 | 123.49 |
| Current amounts owed by group member comp. | 485.65 | 442.33 | 519.01 | 473.79 | 200.60 |
| Current deferred tax assets | 22.23 | 523.50 | 13.17 | 9.38 | 117.48 |
| Short term receivables total | 622.83 | 1 061.08 | 594.49 | 605.57 | 441.56 |
| Cash and bank deposits | 1 446.42 | 1 940.99 | 729.86 | 1 434.36 | 2 528.35 |
| Cash and cash equivalents | 1 446.42 | 1 940.99 | 729.86 | 1 434.36 | 2 528.35 |
| Balance sheet total (assets) | 22 299.54 | 20 729.79 | 22 447.82 | 24 158.03 | 24 482.61 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 500.55 | 500.55 | 500.55 | 500.55 | 500.55 |
| Shares repurchased | 2 000.00 | ||||
| Retained earnings | 19 093.12 | 21 656.93 | 20 132.14 | 21 863.21 | 21 270.03 |
| Profit of the financial year | 2 563.81 | -1 524.79 | 1 731.07 | 1 406.82 | 450.71 |
| Shareholders equity total | 22 157.48 | 20 632.69 | 22 363.76 | 23 770.58 | 24 221.29 |
| Non-current liabilities total | |||||
| Current trade creditors | 19.90 | 19.50 | 19.83 | 21.83 | 21.50 |
| Short-term deferred tax liabilities | 43.32 | 279.03 | |||
| Other non-interest bearing current liabilities | 78.84 | 77.60 | 64.23 | 86.59 | 239.82 |
| Current liabilities total | 142.06 | 97.10 | 84.06 | 387.45 | 261.32 |
| Balance sheet total (liabilities) | 22 299.54 | 20 729.79 | 22 447.82 | 24 158.03 | 24 482.61 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated